我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
30
5 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
16
53.3%
尚未招募
5
16.7%
招募中
8
26.7%
终止
1
3.3%
暂无批准数据
- Researchers at The Chinese University of Hong Kong conducted the world's first randomized clinical trial evaluating GLP-1 receptor agonists in severe stroke patients undergoing reperfusion therapy. - The Phase 2 trial involving 140 patients demonstrated that semaglutide is safe and well-tolerated in acute stroke settings with no severe adverse events attributed to the drug. - Exploratory analyses revealed a potential 20% improvement in neurological recovery among patients who did not receive intravenous thrombolysis before thrombectomy. - The findings provide early clinical evidence supporting the safety of GLP-1RAs in stroke treatment and pave the way for larger Phase 3 trials to confirm neuroprotective potential.
